Acute megakaryocytic leukemia: What have we learned
| Autor: | Philippe Prouet, Bojia Li, Andrew W. Hahn, Ranjan Pathak, Smith Giri, Michael Gary Martin |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Prognostic factor Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Leukemia Megakaryoblastic Acute hemic and lymphatic diseases medicine Humans Transplantation Homologous GATA1 Transcription Factor Protein Kinase Inhibitors Aurora Kinase A Chromosome Aberrations business.industry Valproic Acid Hematopoietic Stem Cell Transplantation Myeloid leukemia Hematology Azepines medicine.disease Prognosis Survival Analysis Molecular analysis Leukemia 030104 developmental biology Pyrimidines Treatment Outcome Oncology 030220 oncology & carcinogenesis Immunology Core Binding Factor Alpha 2 Subunit Cancer research Treatment strategy Allogeneic hematopoietic stem cell transplant Chromosomes Human Pair 3 business Megakaryocytes |
| Zdroj: | Blood reviews. 30(1) |
| ISSN: | 1532-1681 |
| Popis: | Acute megakaryocytic leukemia (AMegL) is a biologically heterogenous subtype of acute myeloid leukemia (AML) that arises from megakaryocytes. Improvements in the accuracy of diagnosing AMegL as well as interest in the molecular analysis of leukemias have led to an increased amount of data available on this rare AML subtype. In this review, we will analyze the diverse molecular features unique to AMegL and how they have influenced the development of novel treatment strategies, including polyploidization. The review will also consider the data available on clinical outcomes in AMegL and how it is a poor individual prognostic factor for AML. Finally, the role of allogeneic hematopoietic stem cell transplant in AMegL will be explored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect